Bringing Novel Class of Vaccine Targets into Development – Camyopeptides Derived from Tumour-Specific IncRNAs
Time: 9:00 am
day: Day Two
Details:
- Results from the profiling of over 1500+ tumour biopts and neoantigen landscapes
- First glance at immunological responses revealing first-in-class potential of shared tumor targets
- Designing the mRNA-LNP cancer vaccine
